| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | MGRG3; MRGX2 |
| Entrez GeneID | 117194 |
| clone | 1C5C3 |
| WB Predicted band size | 37kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human MRGPRX2 expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于MRGPRX2抗体的3篇参考文献示例(文献信息为模拟，实际引用需核实)：
---
1. **文献名称**: *MRGPRX2 Antibody Inhibits Substance P-Induced Mast Cell Activation*
**作者**: McNeil BD, et al.
**摘要**: 研究开发了一种特异性抗MRGPRX2的单克隆抗体，证实其可阻断P物质诱导的肥大细胞脱颗粒和炎症介质释放，为治疗肥大细胞相关过敏性疾病提供潜在策略。
2. **文献名称**: *Targeting MRGPRX2 with Neutralizing Antibodies Attenuates Chronic Urticaria Symptoms*
**作者**: Gaudenzio N, et al.
**摘要**: 通过动物模型和体外实验，证明抗MRGPRX2抗体能显著减少慢性荨麻疹中肥大细胞的异常活化，降低组胺和细胞因子水平，缓解皮肤炎症反应。
3. **文献名称**: *MRGPRX2-Specific Antibodies Reveal Receptor Dysregulation in Atopic Dermatitis*
**作者**: Subramanian H, et al.
**摘要**: 利用抗MRGPRX2抗体发现特应性皮炎患者皮肤中受体表达异常上调，且抗体阻断可减少神经肽介导的炎症通路，提示其作为生物标志物和治疗靶点的潜力。
---
**注**：以上为模拟参考文献，实际研究中需通过PubMed、Google Scholar等平台检索真实文献(关键词：MRGPRX2 antibody, mast cell, therapeutic targeting)。
MRGPRX2 (Mas-related G protein-coupled receptor X2) is a class A GPCR primarily expressed in mast cells, with roles in immune responses, inflammation, and pain modulation. Unlike traditional IgE-mediated pathways, MRGPRX2 activation triggers mast cell degranulation via neuropeptides (e.g., substance P), antimicrobial peptides, and certain drugs, contributing to pseudoallergic reactions and chronic inflammatory conditions. Its unique ligand-binding profile and signaling mechanisms have made it a therapeutic target for mast cell-related disorders, such as chronic urticaria, atopic dermatitis, and drug hypersensitivity.
Antibodies targeting MRGPRX2 are emerging as tools to study receptor function and potential therapeutics. They aim to block pathogenic mast cell activation while preserving IgE-mediated protective immunity. Recent studies highlight their ability to inhibit neuropeptide-induced inflammation and reduce symptoms in preclinical models. Challenges include ensuring specificity (to avoid cross-reactivity with homologous receptors like MRGPRX1) and optimizing pharmacokinetics for clinical use. Research also explores MRGPRX2's role in non-allergic diseases, including fibrosis and pain, expanding potential antibody applications. However, the receptor's complex ligand interactions and tissue-specific signaling require further characterization to advance antibody-based therapies.
×
